Recent Company News

• 09:46 PM ET Aug 28, 2025
  

  Radiopharm Theranostics reports FY EPS (A$0.02) vs FactSet (A$0.02) [5 est, (A$0.04)-(0.02)] - Appendix 4E ($5.70, 0.00)

• 07:38 AM ET Jul 29, 2025
  

  Follow-up: Radiopharm Theranostics issues press release on FY25 financial results and business update ($4.75, 0.00)

• 08:00 PM ET Jul 28, 2025
  

  Radiopharm Theranostics reports Q4 net cash from / (used in) operating activities (A$7.0M) - Appendix 4C ($4.75, 0.00)

• 06:33 PM ET Jul 27, 2025
  

  FDA provides clearance for Radiopharm Theranostic to initiate first-in-human Phase 1 clinical trial of RV-01 ($4.71, 0.00)

• 04:29 PM ET Jul 21, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:44 AM ET Jul 21, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:34 AM ET Jul 21, 2025
  

  Radiopharm Theranostics initiated buy at Brookline Capital Markets ($4.43, 0.00)

• 07:03 PM ET Jul 15, 2025
  

  Radiopharm Theranostics receives A$4.5M R&D tax refund for FY24 ($4.22, 0.00)

• 08:06 AM ET Jun 24, 2025
  

  Radiopharm Theranostics and Cyclotek sign clinical supply agreement for ¹⁶¹Tb-KLK3-mAb phase I clinical trial in Australia ($4.39, 0.00)

• 06:31 PM ET Jun 10, 2025
  

  Radiopharm Theranostics granted Fast Track Designation by US FDA for RAD101 in imaging of brain metastasis ($4.97, 0.00)